Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

Overview of attention for article published in Frontiers in Molecular Biosciences, September 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

Comparison of the Pathological Complete Response Rate and Survival between HER2-low and HER2-zero Breast Cancer in Neoadjuvant Chemotherapy Setting: a Systematic Review and Meta-analysis

Article in Clinical Breast Cancer (May 2024)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis

Article in World Journal of Surgical Oncology (April 2024)

Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

Article in ESMO Open (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.